Danaher Corporation (DHR)

NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-15

$229.04-1.06%

Close 2026-10-16 · 1-day change

Read the published Living FV report summary

Investment OutlookAs of Oct 15, 2026

What could strengthen or challenge Danaher Corporation’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

-0.0%

+10% or more+5%0%−5%−10% or less

9.30 → 9.30 EPS · FY ending Dec 31, 2027 · 14 analysts

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

Change in the same fiscal period’s mean EPS estimate from Sep 15, 2026 to Oct 15, 2026: (new ÷ prior − 1). Contributor count changed from 15 to 14; this is not the number of analysts revising. Source: FMP consensus snapshots. The ±10% axis is a display range.

Living FV™

Living Fair Value by QuarterlyIQ

A valuation that evolves as the business changes.

A published Living FV snapshot is not available yet. The valuation workflow remains discoverable; a market target cannot supply the missing evidence.

View Living FV report and workflow

What the Thesis Depends On

Three key conditions need to be met for the investment thesis to play out.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Increase adjusted EPS to $8.35-$8.55 in 2026	A primary condition in Danaher Corporation's published investment case. The stated target is $8.35 to $8.55 per share.	Under Pressure	Adjusted EPS guidance falls below $8.35 for FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Announce and execute share buyback program	A supporting condition in Danaher Corporation's published investment case. The stated target is Maintain active share buyback program.	Intact	No share buyback activity announced or executed in next 12 months	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 15, 2026Last status assessment Oct 15, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Grow core revenue 3% to 6% annually	A primary condition in Danaher Corporation's published investment case. The stated target is 3% to 6% YoY.	Under Pressure	YoY revenue growth falls below 3% in FY26	Revenue growth: 5.54% FY2026-Q2; GAAP. Published target: 3% to 6% YoY. Target period is not explicitly aligned with this observation. Source published Jul 21, 20265.542453 percent · calculatedSource reportLast status assessment Oct 15, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 26, 2026 Source: company_financial_results. Reference: 6753c89c-6528-49b0-a721-ab322c7a4f03. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 4 of last 4 quarters. Revenue grew from $23.9B in 2024 to $24.6B in 2025 (+3.0%) and $12.2B in first half 2026 vs $11.7B prior year (+4.5%). Management's guidance for 2026 core revenue growth of 3% to 6% aligns with this trajectory, indicating delivery on growth expectations. Delivery assessment Oct 15, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$9.30

$9.27 → $9.30 · observed estimates

FY2027 revenue$28.48B

$28.37B → $28.48B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$9.27	$28,369,884,880	21 / 20
2026-07-25	$9.26	$28,358,984,880	22 / 20
2026-07-26	$9.22	$28,087,924,546	13 / 16
2026-07-27	$9.26	$28,358,984,880	22 / 20
2026-07-28	$9.26	$28,358,984,880	22 / 20
2026-07-29	$9.26	$28,358,733,220	23 / 21
2026-07-30	$9.23	$28,156,028,894	13 / 16
2026-07-31	$9.25	$28,238,336,030	13 / 16
2026-08-01	$9.25	$28,238,336,030	13 / 16
2026-08-02	$9.29	$28,453,095,130	23 / 21
2026-08-03	$9.29	$28,453,095,130	23 / 21
2026-08-04	$9.26	$28,378,073,172	13 / 16
2026-08-05	$9.26	$28,378,073,172	13 / 16
2026-08-06	$9.26	$28,378,073,172	13 / 16
2026-08-07	$9.26	$28,378,073,172	13 / 16
2026-08-08	$9.30	$28,464,160,010	24 / 22
2026-08-09	$9.30	$28,464,160,010	24 / 22
2026-08-10	$9.30	$28,464,160,010	24 / 22
2026-08-11	$9.26	$28,378,073,172	13 / 16
2026-08-12	$9.30	$28,464,160,010	24 / 22
2026-08-13	$9.26	$28,378,073,172	13 / 16
2026-08-14	$9.26	$28,378,073,172	13 / 16
2026-08-15	$9.26	$28,378,073,172	14 / 17
2026-08-16	$9.26	$28,378,073,172	14 / 17
2026-08-17	$9.26	$28,378,073,172	14 / 17
2026-08-18	$9.26	$28,378,073,172	14 / 17
2026-08-19	$9.26	$28,378,073,172	14 / 17
2026-08-20	$9.30	$28,463,708,681	14 / 17
2026-08-21	$9.30	$28,463,708,681	15 / 18
2026-08-22	$9.29	$28,390,992,361	15 / 18
2026-08-23	$9.29	$28,390,992,361	15 / 18
2026-08-24	$9.29	$28,390,992,361	15 / 18
2026-08-25	$9.29	$28,390,992,361	15 / 18
2026-08-26	$9.29	$28,390,992,361	15 / 18
2026-08-27	$9.29	$28,390,992,361	15 / 18
2026-08-28	$9.29	$28,390,992,361	15 / 18
2026-08-29	$9.29	$28,390,992,361	15 / 18
2026-08-30	$9.29	$28,390,992,361	15 / 18
2026-08-31	$9.29	$28,390,992,361	15 / 18
2026-09-01	$9.29	$28,390,992,361	15 / 18
2026-09-02	$9.29	$28,385,835,733	15 / 18
2026-09-03	$9.29	$28,385,835,733	15 / 18
2026-09-04	$9.29	$28,385,835,733	15 / 18
2026-09-05	$9.29	$28,385,835,733	15 / 18
2026-09-06	$9.29	$28,385,835,733	15 / 18
2026-09-07	$9.29	$28,385,835,733	15 / 18
2026-09-08	$9.29	$28,385,835,733	15 / 18
2026-09-09	$9.29	$28,385,835,733	15 / 18
2026-09-10	$9.30	$28,448,473,396	15 / 18
2026-09-11	$9.30	$28,448,473,396	15 / 18
2026-09-12	$9.30	$28,448,473,396	15 / 18
2026-09-13	$9.30	$28,448,473,396	15 / 18
2026-09-14	$9.30	$28,448,473,396	15 / 18
2026-09-15	$9.30	$28,448,473,396	15 / 18
2026-09-16	$9.30	$28,448,473,396	15 / 18
2026-09-17	$9.30	$28,448,473,396	15 / 18
2026-09-18	$9.30	$28,448,473,396	15 / 18
2026-09-19	$9.30	$28,448,473,396	15 / 18
2026-09-20	$9.30	$28,448,473,396	15 / 18
2026-09-21	$9.30	$28,448,473,396	15 / 18
2026-09-22	$9.30	$28,450,523,788	15 / 18
2026-09-23	$9.30	$28,450,523,788	15 / 18
2026-09-24	$9.30	$28,450,523,788	15 / 18
2026-09-25	$9.30	$28,452,337,299	15 / 18
2026-09-26	$9.30	$28,452,337,299	15 / 18
2026-09-27	$9.30	$28,452,337,299	15 / 18
2026-09-28	$9.30	$28,452,337,299	15 / 18
2026-09-29	$9.30	$28,452,337,299	15 / 18
2026-09-30	$9.30	$28,454,807,176	15 / 18
2026-10-01	$9.30	$28,454,807,176	14 / 18
2026-10-02	$9.30	$28,454,814,002	14 / 18
2026-10-03	$9.30	$28,454,814,002	14 / 18
2026-10-04	$9.30	$28,454,814,002	14 / 18
2026-10-05	$9.30	$28,454,814,002	14 / 18
2026-10-06	$9.30	$28,454,841,275	14 / 18
2026-10-07	$9.30	$28,454,841,275	14 / 18
2026-10-08	$9.30	$28,475,690,692	14 / 18
2026-10-09	$9.30	$28,476,022,510	14 / 18
2026-10-10	$9.30	$28,480,010,013	14 / 18
2026-10-11	$9.30	$28,480,010,013	14 / 18
2026-10-12	$9.30	$28,480,010,013	14 / 18
2026-10-13	$9.30	$28,480,010,013	14 / 18
2026-10-14	$9.30	$28,480,689,888	14 / 18
2026-10-15	$9.30	$28,480,689,888	14 / 18

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	23	2
2026-06-01	23	4
2026-07-01	23	4
2026-08-01	22	4
2026-09-01	22	4
2026-10-01	22	3

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 22 Buy / Strong Buy · 3 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades5 maintains

Recent actions · Sep 16–Oct 15 · 5 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Morgan StanleyOct 12

$240.00New observation · no comparable prior

RBC CapitalOct 5 · prior Jul 22

$215.00 → $250.00+16.3%

GuggenheimOct 1 · prior Jul 22

$200.00 → $250.00+25.0%

$0$137.50$275.00

2 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 16, 2026–Oct 15, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Increase adjusted EPS to $8.35-$8.55 in 2026Published status: Under Pressure
Announce and execute share buyback programQualitative condition
Grow core revenue 3% to 6% annuallyPublished status: Under Pressure

Next proof point

Oct 21, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.3%Typical daily move · historical

Downside history

-33.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Danaher Corporation outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 10, 2026

What kind of bet this is

This is a durable compounder with a focus on steady revenue growth and earnings improvement. The current thesis state is intact, supported by recent financial performance and management's commitment to growth.

What's priced into Danaher Corporation

The valuation is considered expensive compared to peers, indicating that the market has high expectations for future performance. The expectations gap is slightly negative, suggesting that some caution is already priced into the stock.

What the fundamentals likely do

Fundamentals are likely to show continued growth, as management aims for core revenue growth of 3% to 6% in 2026. Recent results have been strong, but there is a moderate risk of missing expectations due to industry trends.

What Danaher Corporation hinges on

The thesis hinges on management's ability to meet growth targets and the overall health of the healthcare sector. Key factors include guidance updates and performance from sector bellwethers, which could influence sentiment.